Article may be outdated

This article is 9 days old. Some details may have changed since publication.

EMJ·3 min read·medium

Chronic Hives Drug Fails to Beat Placebo

A
anayamalik
Chronic Hives Drug Fails to Beat Placebo
✦AI Summary

A Phase II clinical trial for the experimental drug EP262 failed to show significant improvement in chronic spontaneous urticaria symptoms compared to a placebo. Despite being well-tolerated by patients, the study was terminated due to a lack of efficacy.

Why it matters

This result represents a setback in the development of new treatments for chronic hives, highlighting the challenges of targeting specific receptors like MRGPRX2.

✦Dive DeeperCreate a free account to unlock

CHRONIC hives symptoms improved with experimental oral EP262, but neither dose outperformed placebo in a randomized trial. The Phase II CALM-CSU study found no significant additional benefit for disease activity, itch, or hive severity after six weeks of treatment alongside stable daily H1 antihistamines.

Chronic spontaneous urticaria (CSU) causes itchy wheals, angioedema, or both for more than six weeks without a known external trigger. EP262 targets Mas-related G protein–coupled receptor X2 (MRGPRX2), a receptor on skin mast cells associated with immunoglobulin E (IgE)-independent degranulation.

The multicenter, double-blind study randomized 113 adults to oral EP262 50 mg, EP262 150 mg, or placebo once daily. Eligible patients were aged 18–80 years, had CSU for at least six months, and had a Urticaria Activity Score over seven days (UAS7) of at least 16 despite receiving stable daily H1 antihistamines. Overall, 107 patients completed treatment.

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
sciencehealth
✦

Get smarter about the news

Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.

Create free account

Already have an account? Sign in